<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-COM-2671</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2671</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>Содержание медиаторов врожденного иммунитета в слезной жидкости пациентов с сосудистыми и нейродегенеративными проявлениями диабетической ретинопатии</article-title><trans-title-group xml:lang="en"><trans-title>Content of mediators of innate immunity in the tears of patients with vascular and neurodegenerative manifestations of diabetic retinopathy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8966-3120</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ручкин</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Ruchkin</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ручкин Михаил Петрович — заочный аспирант кафедры нормальной и патологической физиологии ФГБОУ ВО «ТГМУ» МЗ РФ; врач-офтальмолог ООО «Приморский центр микрохирургии глаза».</p><p>690002, Владивосток, пр. Острякова, 2</p><p>Тел.: 8 (924) 137-04-78</p></bio><bio xml:lang="en"><p>Mikhail P. Ruchkin - Postgraduate Student, Department of Normal and Pathological Physiology, Pacific State Medical University; Ophthalmologist, Primorsky Eye Microsurgery Center.</p><p>2 Ostryakov Ave, Vladivostok 690002Phone: +7 (924) 137-04-78</p></bio><email xlink:type="simple">michaelr-n@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6632-9800</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркелова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Markelova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маркелова Елена Владимировна — доктор медицинских наук, профессор, заведующая кафедрой нормальной и патологической физиологии.</p><p>Владивосток</p></bio><bio xml:lang="en"><p>Elena V. Markelova - PhD, MD (Medicine), Head, Department of Normal and Pathological Physiology, Pacific State Medical University.</p><p>Vladivostok</p></bio><email xlink:type="simple">markev2010@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федяшев</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedyashev</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Федяшев Глеб Арнольдович — доктор медицинских наук, профессор кафедры офтальмологии и оториноларингологии ФГБОУ ВО «ТГМУ» МЗ РФ; главный врач ООО «Приморский центр микрохирургии глаза».</p><p>Владивосток</p></bio><bio xml:lang="en"><p>Gleb A. Fedyashev - PhD, MD (Medicine), Professor, Department of Ophthalmology and Otorhinolaryngology, Pacific State Medical University; Head Physician, Primorsky Eye Microsurgery Center.</p><p>Vladivostok</p></bio><email xlink:type="simple">fediashev@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Тихоокеанский государственный медицинский университет» Министерства здравоохранения РФ; ООО «Приморский центр микрохирургии глаза»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pacific State Medical University; Primorsky Eye Microsurgery Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Тихоокеанский государственный медицинский университет» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pacific State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>06</month><year>2023</year></pub-date><volume>25</volume><issue>5</issue><fpage>1007</fpage><lpage>1012</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ручкин М.П., Маркелова Е.В., Федяшев Г.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Ручкин М.П., Маркелова Е.В., Федяшев Г.А.</copyright-holder><copyright-holder xml:lang="en">Ruchkin M.P., Markelova E.V., Fedyashev G.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2671">https://www.mimmun.ru/mimmun/article/view/2671</self-uri><abstract><p>По результатам последних исследований диабетическую ретинопатию можно рассматривать не только как сосудистое заболевание, но и как нейродегенеративный процесс. Изучение состава слезной жидкости используется для оценки состояния локального иммунитета при развитии глазных заболеваний. Однако исследования, изучающие влияние состава слезы при диабетической ретинопатии немногочисленны. Цель исследования — определить уровни IL-1β, IL-10, TGF-β3, MMP-7, TIMP-2, белка S100b, BDNF и NGF в слезной жидкости пациентов сосудистыми и нейродегенеративными проявлениями диабетической ретинопатии. В исследование были включены 80 пациентов с диагнозом сахарный диабет 2 типа, которые были разделены на 2 группы: группа 1 — 40 пациентов, у которых не было клинических признаков диабетической ретинопатии на глазном дне, группа 2 — 40 пациентов с начальными признаками непролиферативной диабетической ретинопатии. Всем включенным в исследование проводилось обследование на оптическом когерентном томографе RTVue-100 (США), определяли объем фокальных потерь ганглиозных клеток сетчатки (FLV). Увеличение FLV выше показателей нормативной базы прибора расценивали как ОКТ-признак нейродегенерации сетчатки. По результатам ОКТ участников первой и второй группы дополнительно разделили на 4 подгруппы: 1А — пациенты без сосудистых изменений на глазном дне и без ОКТ-признаков нейродегенерации сетчатки (n = 12), 1Б — пациенты без сосудистых изменений на глазном дне и с наличием ОКТ-признаков нейродегенерации сетчатки (n = 28), 2А — пациенты с начальной непролиферативной ДР и без ОКТ-признаков нейродегенерации сетчатки (n = 10), 2Б — пациенты с начальной непролиферативной ДР и с ОКТ-признаками нейродегенерации сетчатки (n = 30). Уровень IL-1β, IL-10, TGF- β3, MMP-7, TIMP-2, белка S100b, BDNF и NGF в слезной жидкости определяли с помощью иммуноферментного анализа. Уровни IL-1β и IL-10 в слезной жидкости во всех подгруппах были сопоставимы с контролем на протяжении всего исследования. Содержание TGF-β3 в слезной жидкости пациентов группы с начальными признаками непролиферативной ДР (группа 2) было достоверно (p = 0,001) ниже в сравнении с контролем и группой 2. Однако отсутствовала достоверная разница (p &gt; 0,05) между подгруппами А и Б внутри групп. Концентрация MMP-7 в слезной жидкости во всех подгруппах была достоверно ниже чем в контроле (p &lt; 0,05), однако, в подгруппах с ОКТ-признаками нейродегенерации сетчатки (1Б и 2Б) дефицит данной металлопротеиназы был более выражен (p = 0,0001). Уровни исследуемых нейропептидов NGF, BDNF и S100B в слезной жидкости не отличались от контроля во всех подгруппах.</p></abstract><trans-abstract xml:lang="en"><p>According to the results of recent studies, diabetic retinopathy can be considered not only as a vascular disease, but also as a neurodegenerative process. Study of the composition of the tear fluid is used to assess the state of local immunity in the development of eye diseases. However, studies examining the effect of tear composition in diabetic retinopathy are few. The aim of the study is to determine the levels of IL-1β, IL-10, TGF-β3, MMP-7, TIMP-2, protein S100b, BDNF and NGF in the tear fluid ofpatients with vascular and neurodegenerative manifestations of diabetic retinopathy. The study included 80 patients diagnosed with type 2 diabetes which were divided into 2 groups: the 1st group included 40 patients who had no clinical signs of diabetic retinopathy on the fundus; the 2nd group included 40 patients with initial signs of non-proliferative diabetic retinopathy. All those included in the study were examined on an optical coherent tomograph RTVue-100 (USA); the volume of focal losses of retinal ganglion cells (FLV) was determined. An increase in FLV above the normative base of the device was regarded as an OCT-sign of retinal neurodegeneration. According to the results of OCT, the participants of the first and second groups were additionally divided into 4 subgroups: 1A — patients without vascular changes in the fundus and without OCT signs of retinal neurodegeneration (n = 12); 1B — patients without vascular changes in the fundus and with the presence of OCT signs of retinal neurodegeneration (n = 28); 2A — patients with initial non-proliferative DR and without OCT signs of retinal neurodegeneration (n = 10); and 2B — patients with initial non-proliferative DR and with OCT signs of retinal neurodegeneration (n = 30). The levels of IL-1β, IL-10, TGF-β3, MMP-7, TIMP-2, protein S100 b, BDNF, and NGF in tear fluid were determined by enzyme-linked immunosorbent assay. Levels of IL-1β and IL-10 in tear fluid in all subgroups were comparable to controls throughout the study. TGF-β3 content in the tear fluid of patients in the group with initial signs of non-proliferative DR (group 2) was significantly (p = 0.001) lower compared with control and group 2. However, there was no significant difference (p &gt; 0.05) between subgroups A and B within groups. The concentration of MMP-7 in the tear fluid in all subgroups was significantly lower than in the control (p &lt; 0.05). However, in the subgroups with OCT signs of retinal neurodegeneration (1B and 2B), the deficiency of this metalloproteinase was more pronounced (p = 0.0001). The levels of the neuropeptides under study NGF, BDNF and S100 B in tear fluid did not differ from controls in all subgroups.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нейродегенерация</kwd><kwd>цитокины</kwd><kwd>нейропептиды</kwd><kwd>матриксные металлопротеиназы</kwd><kwd>диабетическая ретинопатия</kwd><kwd>слеза</kwd></kwd-group><kwd-group xml:lang="en"><kwd>neurodegeneration</kwd><kwd>cytokines</kwd><kwd>neuropeptides</kwd><kwd>matrix metalloproteinases</kwd><kwd>diabetic retinopathy</kwd><kwd>tear</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Behl T., Kaur G., Sehgal A., Bhardwaj S., Singh S., Buhas C., Judea-Pusta C., Uivarosan D., Munteanu M.A., Bungau S. Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: Pathophysiological and therapeutic perspectives. Int. J. Mol. Sci., 2021, Vol. 22, no. 3, pp. 1413-1423.</mixed-citation><mixed-citation xml:lang="en">Behl T., Kaur G., Sehgal A., Bhardwaj S., Singh S., Buhas C., Judea-Pusta C., Uivarosan D., Munteanu M.A., Bungau S. Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: Pathophysiological and therapeutic perspectives. Int. J. Mol. Sci., 2021, Vol. 22, no. 3, pp. 1413-1423.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Neroev V.V., Chesnokova N.B., Pavlenko T.A. Variations of concentrations of angiotensin II, angiotensin-converting enzyme and matrix metalloproteinase-9 in tears and serum of patients with diabetic retinopathy. Ophthalmology in Russia, 2020, Vol. 17, no. 4, pp. 771-778. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Neroev V.V., Chesnokova N.B., Pavlenko T.A. Variations of concentrations of angiotensin II, angiotensin-converting enzyme and matrix metalloproteinase-9 in tears and serum of patients with diabetic retinopathy. Ophthalmology in Russia, 2020, Vol. 17, no. 4, pp. 771-778. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Poteryaeva O.N., Russkih G.S., Zubova A.V., Gevorgyan M.M., Usynin I.F. Changes in activity of matrix metalloproteinases, concentration of proinsulin and C-peptide in serum depending on the stage compensation of diabetes mellitus. Bulletin of Experimental Biology and Medicine, 2017, Vol. 164, no. 12, pp. 697-700. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Poteryaeva O.N., Russkih G.S., Zubova A.V., Gevorgyan M.M., Usynin I.F. Changes in activity of matrix metalloproteinases, concentration of proinsulin and C-peptide in serum depending on the stage compensation of diabetes mellitus. Bulletin of Experimental Biology and Medicine, 2017, Vol. 164, no. 12, pp. 697-700. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ruchkin M.P., Kuvshinova E.R., Fedyashev G.A., Markelova E.V. Neurodegeneration of retina in patients with type 2 diabetes mellitus. Pacific Medical Journal, 2020, no. 3, pp. 62-64. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Ruchkin M.P., Kuvshinova E.R., Fedyashev G.A., Markelova E.V. Neurodegeneration of retina in patients with type 2 diabetes mellitus. Pacific Medical Journal, 2020, no. 3, pp. 62-64. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ruchkin M.P., Markelova E.V., Fedyashev G.A., Yushchuk V.N. Role of cytokines, neuropeptides and matrix metalloproteinases in the immunopathogeneses of retinal neurodegeneration in diabetic retinopathy. Russian Journal of Immunology, 2022, Vol. 25, no. 4, pp. 515-520. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Ruchkin M.P., Markelova E.V., Fedyashev G.A., Yushchuk V.N. Role of cytokines, neuropeptides and matrix metalloproteinases in the immunopathogeneses of retinal neurodegeneration in diabetic retinopathy. Russian Journal of Immunology, 2022, Vol. 25, no. 4, pp. 515-520. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Saucedo L., Pfister I.B., Zandi S., Gerhardt C., Garweg J.G. Ocular TGF-в, matrix metalloproteinases, and TIMP-1 increase with the development and progression of diabetic retinopathy in type 2 diabetes mellitus. Mediators Inflamm., 2021, Vol. 25, no. 2021, 9811361. doi: 10.1155/2021/9811361.</mixed-citation><mixed-citation xml:lang="en">Saucedo L., Pfister I.B., Zandi S., Gerhardt C., Garweg J.G. Ocular TGF-в, matrix metalloproteinases, and TIMP-1 increase with the development and progression of diabetic retinopathy in type 2 diabetes mellitus. Mediators Inflamm., 2021, Vol. 25, no. 2021, 9811361. doi: 10.1155/2021/9811361.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Simo R., Stitt A.W., Gardner T.W. Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia, 2018, Vol. 61, no. 9, pp. 1902-1912.</mixed-citation><mixed-citation xml:lang="en">Simo R., Stitt A.W., Gardner T.W. Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia, 2018, Vol. 61, no. 9, pp. 1902-1912.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Soni D., Sagar P., Takkar B. Diabetic retinal neurodegeneration as form of diabetic retinopathy. Int. Ophthalmol., 2021, Vol. 41, no. 9, pp. 3223-3248.</mixed-citation><mixed-citation xml:lang="en">Soni D., Sagar P., Takkar B. Diabetic retinal neurodegeneration as form of diabetic retinopathy. Int. Ophthalmol., 2021, Vol. 41, no. 9, pp. 3223-3248.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Uzel A.G.T., UGurlu N., Toklu Y., Çİçek M., Boral B., Şener B., ÇaĞil N. Relationship between stages of diabetic retinopathy and levels of brain-derived neurotrophic factor in aqueous humor and serum. Retina, 2020, Vol. 40, no. 1, pp. 121-125.</mixed-citation><mixed-citation xml:lang="en">Uzel A.G.T., UGurlu N., Toklu Y., Q^ek M., Boral B., §ener B., ^aGil N. Relationship between stages of diabetic retinopathy and levels of brain-derived neurotrophic factor in aqueous humor and serum. Retina, 2020, Vol. 40, no. 1, pp. 121-125.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
